Universität zu Köln

Ghia, Paolo ORCID: 0000-0003-3750-7342 and Hallek, Michael (2014). Management of chronic lymphocytic leukemia. Haematologica, 99 (6). S. 965 - 973. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Full text not available from this repository.

Abstract

In the last decade, the management of chronic lymphocytic leukemia has undergone profound changes that have been driven by an improved understanding of the biology of the disease and the approval of several new drugs. Moreover, many novel drugs are currently under evaluation for rapid approval or have been approved by regulatory agencies, further broadening the available therapeutic armamentarium for patients with chronic lymphocytic leukemia. The use of novel biological and genetic parameters combined with a careful clinical evaluation allows us to dissect some of the heterogeneity of the disease and to distinguish patients with a very mild onset and course, who often will not need any treatment, from those with an intermediate prognosis and a third group with a very aggressive course (high-risk leukemia). On this background, it becomes increasingly challenging to select the right treatment strategy. In this paper, we describe our own approach to the management of different patients with chronic lymphocytic leukemia.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Ghia, Paolo UNSPECIFIED orcid.org/0000-0003-3750-7342 UNSPECIFIED Hallek, Michael UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-436308
DOI:	10.3324/haematol.2013.096107
Journal or Publication Title:	Haematologica
Volume:	99
Number:	6
Page Range:	S. 965 - 973
Date:	2014
Publisher:	FERRATA STORTI FOUNDATION
Place of Publication:	PAVIA
ISSN:	0390-6078
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language PREVIOUSLY UNTREATED PATIENTS; HIGH-DOSE METHYLPREDNISOLONE; B-CELL LYMPHOCYTOSIS; PHASE-III TRIAL; RESIDUAL DISEASE; AUTOIMMUNE CYTOPENIA; RITUXIMAB REGIMEN; PLUS CHLORAMBUCIL; 1ST REMISSION; FLUDARABINE Multiple languages Hematology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/43630